A downtrend has been apparent in Adherex Technologies Inc. (FENC) lately with too much selling pressure. The stock has declined 22.2% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround.Here is How to Spot Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indic ...

Financial Performance - As of December 31, 2024, the company had $24.6 million in money market investments, an increase from $11.9 million at December 31, 2023, indicating a significant growth in liquid assets [555]. - The company has not experienced any loss or write-down of its money market investments for the years ended December 31, 2024, and 2023, reflecting stable investment performance [556]. - The company has a history of significant losses and limited revenue generation from product sales since inception, highlighting financial challenges [15]. Investment Strategy - The investment policy prioritizes preservation of principal, liquidity, and return on investment, with minimal risk associated with fluctuating interest rates [557]. Regulatory and Market Challenges - The commercialization of PEDMARK® is critical, as the company is a single product entity with limited commercial experience, complicating future financial forecasts [19]. - Regulatory approvals for PEDMARK® have been obtained, but ongoing regulatory review and potential restrictions remain a concern for market acceptance [19]. - The company may require additional financing for further product development and regulatory approvals, which could impact operational capabilities [15]. - The company faces substantial competition in the biopharmaceutical market, which could adversely affect its market position and financial performance [19]. Operational Risks - The company is subject to foreign currency risks, holding approximately CAD$0.16 million and €0.24 million as of December 31, 2024, to manage obligations in Canada and the EU [558]. - The company relies on third parties for raw materials and manufacturing, and any failure in their performance could materially impact business operations [17].

Exhibit 99.1 FENNEC PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL-YEAR 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE ~ Achieved Full-Year PEDMARK® Net Product Sales of $29.6 Million, Up 40% Year-Over- Year, and Generated PEDMARK® Q4 2024 Net Product Sales of $7.9 Million ~ ~ Delivered Q4 2024 EBITDA Loss of $0.6 Million and Company Has $26.6 Million in Cash, Cash Equivalents and Short-Term Investments ~ ~ Completed Early Repayment of $13 Million of the Company's Convertible Debt Facility ~ ~ PEDMARQ ...

Financial Data and Key Metrics Changes - In 2024, the company reported a revenue growth of approximately 40% year-over-year, with net product sales of $29.6 million compared to $21.3 million in 2023 [28][30] - For Q4 2024, net product sales were $7.9 million, reflecting a quarterly growth rate of approximately 13% [28] - The company managed to burn only approximately $0.6 million in cash for Q4 2024, demonstrating operational efficiency [34] Business Line Data and Key Metrics Changes - The pediatric segment continued to show growth, while the adolescent and young adult (AYA) segment emerged as a significant opportunity [38] - Selling and marketing expenses for Q4 2024 were $3.9 million, down from $4.6 million in Q3 2024, while full-year expenses increased to $18.4 million from $12.1 million in the previous year [29][30] Market Data and Key Metrics Changes - The U.S. AYA oncology landscape is estimated to have approximately 20,000 cisplatin chemotherapy patients treated annually, with significant market potential [11] - The product PEDMARK is gaining traction in major academic centers, which is critical for broader market acceptance [14] Company Strategy and Development Direction - The company is focused on expanding awareness of the unmet need for preventing cisplatin-induced ototoxicity and establishing PEDMARK as the standard of care [9][10] - The PEDMARK strategy will be utilized throughout 2025 to drive growth, with a focus on increasing adoption among oncologists and ensuring access for patients [7][9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth potential for PEDMARK, particularly in the AYA segment, and anticipates significant growth in the second half of 2025 [41][42] - The company is actively engaging with stakeholders to support the inclusion of PEDMARK in key compendia, which is expected to enhance access and reimbursement pathways [17][18] Other Important Information - The company has launched PEDMARQSI in Germany and the U.K., with pricing set at £8277 in the U.K. and over €10,500 in Germany [20][21] - The company anticipates receiving a €10 million milestone upon obtaining final pricing approval in Germany [34] Q&A Session Summary Question: Did the pediatric business return to sequential growth in Q4, and what was the AYA contribution? - Management confirmed continued growth in the pediatric segment and highlighted the AYA segment as an incredible opportunity, though specific breakdowns were not provided [38] Question: What is the expected inflection in the AYA segment for 2025? - Management indicated significant opportunities in the AYA segment and expects accelerated growth in the second half of the year [41][42] Question: What progress has Norgine made in Europe regarding key centers of excellence? - Management noted that the product is now commercially available in the U.K. and Germany, with ongoing updates expected as more countries are approved [48][49] Question: What is the competitive landscape for PEDMARK in the U.S.? - Management acknowledged the presence of compounded products but emphasized the adoption of PEDMARK in major institutions, indicating progress despite competition [72] Question: Will clinical trials be run for potential label expansions? - Management indicated openness to discussions regarding label expansions and will provide updates as developments occur [75]

Adherex Technologies Inc. (FENC) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of $0.56. This compares to loss of $0.10 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -110.71%. A quarter ago, it was expected that this company would post a loss of $0.13 per share when it actually produced a loss of $0.21, delivering a surprise of -61.54%.Over the last four quarters, the company has not b ...

RESEARCH TRIANGLE PARK, N.C., March 06, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its full year and fourth quarter 2024 financial results before the opening of the U.S. financial markets on Monday, March 10, 2025. Management will host a conference call and webcast that day to discuss the Company's financial and business results. Conference Call & Webcast Detail: Date:Monday, ...

Investors in Adherex Technologies (FENC) need to pay close attention to the stock based on moves in the options market lately. That is because the Feb 21, 2025 $05.00 Call had some of the highest implied volatility of all equity options today.What is Implied Volatility?Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could ...

Group 1 - Fennec Pharmaceuticals Inc. will participate in the 15th Annual Craig-Hallum Alpha Select Conference on November 19, 2024, at the Sheraton New York Times Square Hotel [1][2] - The company focuses on the development and commercialization of PEDMARK, aimed at reducing the risk of platinum-induced ototoxicity in pediatric patients [2] - PEDMARK received FDA approval in September 2022, European Commission approval in June 2023, and U.K. approval in October 2023 under the brand name PEDMARQSI [2] Group 2 - PEDMARK has Orphan Drug Exclusivity in the U.S., while PEDMARQSI has received Pediatric Use Marketing Authorization in Europe, providing eight years plus two years of data and market protection [2]

Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q3 2024 Earnings Conference Call November 9, 2024 8:30 AM ET Company Participants Robert Andrade - Chief Financial Officer Jeff Hackman - Chief Executive Officer and Director Conference Call Participants Chase Knickerbocker - Craig-Hallum Raghuram Selvaraju - H.C. Wainwright Operator Good morning, ladies and gentlemen, and welcome to Fennec Pharmaceuticals Third Quarter 2024 Earnings and Corporate Update Conference Call. At this time, all participants are in listen- ...

Financial Performance - PEDMARK achieved net product sales of $6,974,000 for the three months ended September 30, 2024, representing an increase of 7.06% from $6,515,000 in the same period of 2023[148]. - Gross profit for the same period was $5,617,000, down from $6,184,000 in 2023, indicating a decrease of 9.15%[150]. - Net product sales for the nine months ended September 30, 2024, were $21,655, an increase of $10,138 compared to $11,517 in the same period in 2023[156]. - Total net revenue for the nine months ended September 30, 2024, was $39,613, up from $11,517 in 2023, reflecting a change of $28,096[156]. - The company recorded a net loss of $1,549 for the nine months ended September 30, 2024, a significant improvement from a net loss of $13,363 in the same period in 2023[156]. Operating Expenses - Total operating expenses increased to $12,176,000 in Q3 2024, up from $7,532,000 in Q3 2023, reflecting a rise of 61.5%[148]. - Selling and marketing expenses rose to $4,601,000, compared to $3,384,000 in the prior year, marking an increase of 36%[148]. - General and administrative expenses increased by $2,316,000, driven by higher salaries and litigation costs, compared to the same period in 2023[149]. - Selling and marketing expenses increased to $14,482 for the nine months ended September 30, 2024, compared to $8,255 in 2023, primarily due to increased payroll and marketing efforts[157]. - General and administrative expenses rose by $5,240 to $18,857 for the nine months ended September 30, 2024, attributed to higher consulting and professional costs[158]. Research and Development - Research and development expenses rose to $97,000, up from $12,000 in the same quarter of 2023, reflecting an increase of 808.33%[151]. Cash Flow and Financial Position - Cash and cash equivalents increased to $40,320 as of September 30, 2024, from $13,269 at December 31, 2023, driven by cash inflows from the Norgine licensing deal and product sales[162]. - Net cash provided by operating activities for the nine months ended September 30, 2024, was $28,454, compared to a net cash used of $12,283 in 2023[163]. - Interest income rose by $957 to $1,283 for the nine months ended September 30, 2024, due to higher cash balances and interest rates[161]. Strategic Developments - The company received approximately $43,200,000 upfront from an exclusive licensing agreement with Norgine for PEDMARQSI®[138]. - PEDMARK received Orphan Drug Exclusivity from the FDA, providing seven years of market exclusivity until September 20, 2029[141]. - The European Commission granted Marketing Authorization for PEDMARQSI® in June 2023, including a Pediatric Use Marketing Authorization with up to 10 years of market protection[137]. - The company continues to explore strategic collaborations with other pharmaceutical and biotechnology companies to enhance its market position[164]. Shareholder Information - The total outstanding shares increased to 33,027 thousand as of September 30, 2024, from 32,209 thousand at December 31, 2023[165]. Interest and Debt - Interest expense increased by $169,000 due to higher debt levels compared to the same period in 2023[152].